{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T22:35:40Z","timestamp":1776551740331,"version":"3.51.2"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"vor","delay-in-days":33,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04516-0","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:05:54Z","timestamp":1772219154000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Anti-CD38 targeted carfilzomib-loaded hybrid nanocomposites for multiple myeloma therapy: cytotoxicity and biodistribution"],"prefix":"10.1007","volume":"17","author":[{"given":"Deepak","family":"Mishra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asha","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Drishti","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishabh","family":"Kushwaha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priyanka","family":"Ahlawat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viral","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"4516_CR1","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.2147\/cmar.s150653","volume":"11","author":"K Groen","year":"2019","unstructured":"Groen K, Van De Donk NWCJ, Stege C, Zweegman S, Nijhof IS. Carfilzomib for relapsed and refractory multiple myeloma. CMAR. 2019;11:2663\u201375. https:\/\/doi.org\/10.2147\/cmar.s150653.","journal-title":"CMAR"},{"issue":"2","key":"4516_CR2","doi-asserted-by":"publisher","first-page":"103920","DOI":"10.1016\/j.sjbs.2023.103920","volume":"31","author":"MS Abduh","year":"2024","unstructured":"Abduh MS. An overview of multiple myeloma: A monoclonal plasma cell malignancy\u2019s diagnosis, management, and treatment modalities. Saudi J Biol Sci. 2024;31(2):103920. https:\/\/doi.org\/10.1016\/j.sjbs.2023.103920.","journal-title":"Saudi J Biol Sci"},{"issue":"1","key":"4516_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/ejh.12701","volume":"97","author":"A Isidori","year":"2016","unstructured":"Isidori A, Loscocco F, Guiducci B, Malerba L, Clissa C, Visani G. PBSC mobilization in patients with autoimmune diseases: what\u2019s next. Eur J Haematol. 2016;97(1):5\u20136. https:\/\/doi.org\/10.1111\/ejh.12701.","journal-title":"Eur J Haematol"},{"issue":"1","key":"4516_CR4","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/cancers12010159","volume":"12","author":"I Sharafutdinov","year":"2020","unstructured":"Sharafutdinov I, Backert S, Tegtmeyer N, Cortactin. A major cellular target of the gastric carcinogen Helicobacter pylori. Cancers. 2020;12(1):159. https:\/\/doi.org\/10.3390\/cancers12010159.","journal-title":"Cancers"},{"key":"4516_CR5","doi-asserted-by":"publisher","unstructured":"Park JE, Chun SE, Reichel D, Min JS, Lee SC, Han S et al. Polymer micelle formulation for the proteasome inhibitor drug carfilzomib: Anticancer efficacy and pharmacokinetic studies in mice. Ahmad A, editor. PLoS ONE. 2017;12(3):e0173247. https:\/\/doi.org\/10.1371\/journal.pone.0173247","DOI":"10.1371\/journal.pone.0173247"},{"issue":"2","key":"4516_CR6","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1124\/jpet.115.226993","volume":"355","author":"L Ao","year":"2015","unstructured":"Ao L, Reichel D, Hu D, Jeong H, Kim KB, Bae Y, et al. Polymer micelle formulations of proteasome inhibitor Carfilzomib for improved metabolic stability and anticancer efficacy in human multiple myeloma and lung cancer cell lines. J Pharmacol Exp Ther. 2015;355(2):168\u201373. https:\/\/doi.org\/10.1124\/jpet.115.226993.","journal-title":"J Pharmacol Exp Ther"},{"key":"4516_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","volume":"196","author":"L Guilleminault","year":"2014","unstructured":"Guilleminault L, Azzopardi N, Arnoult C, Sobilo J, Herv\u00e9 V, Montharu J, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Controlled Release. 2014;196:344\u201354. https:\/\/doi.org\/10.1016\/j.jconrel.2014.10.003.","journal-title":"J Controlled Release"},{"key":"4516_CR8","doi-asserted-by":"publisher","first-page":"1394393","DOI":"10.3389\/fonc.2024.1394393","volume":"14","author":"D Galas-Filipowicz","year":"2024","unstructured":"Galas-Filipowicz D, Chavda SJ, Gong JN, Huang DCS, Khwaja A, Yong K. Co-operation of MCL-1 and BCL-XL anti-apoptotic proteins in stromal protection of MM cells from Carfilzomib mediated cytotoxicity. Front Oncol. 2024;14:1394393. https:\/\/doi.org\/10.3389\/fonc.2024.1394393.","journal-title":"Front Oncol"},{"key":"4516_CR9","doi-asserted-by":"publisher","first-page":"104365","DOI":"10.1016\/j.jddst.2023.104365","volume":"83","author":"A Tharmatt","year":"2023","unstructured":"Tharmatt A, Sahel DK, Raza K, Pandey MM, Mittal A, Chitkara D. Topical delivery of Anti-VEGF nanomedicines for treating psoriasis. J Drug Deliv Sci Technol. 2023;83:104365. https:\/\/doi.org\/10.1016\/j.jddst.2023.104365.","journal-title":"J Drug Deliv Sci Technol"},{"issue":"1","key":"4516_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2011.09.064","volume":"158","author":"TK Dash","year":"2012","unstructured":"Dash TK, Konkimalla VB. Poly-\u0454-caprolactone based formulations for drug delivery and tissue engineering: A review. J Controlled Release. 2012;158(1):15\u201333. https:\/\/doi.org\/10.1016\/j.jconrel.2011.09.064.","journal-title":"J Controlled Release"},{"issue":"7","key":"4516_CR11","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.3390\/pharmaceutics15071977","volume":"15","author":"A Bhadran","year":"2023","unstructured":"Bhadran A, Shah T, Babanyinah GK, Polara H, Taslimy S, Biewer MC, et al. Recent advances in Polycaprolactones for anticancer drug delivery. Pharmaceutics. 2023;15(7):1977. https:\/\/doi.org\/10.3390\/pharmaceutics15071977.","journal-title":"Pharmaceutics"},{"issue":"2","key":"4516_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.3390\/ijms21020449","volume":"21","author":"R Nanduri","year":"2020","unstructured":"Nanduri R, Furusawa T, Bustin M. Biological functions of HMGN chromosomal proteins. IJMS. 2020;21(2):449. https:\/\/doi.org\/10.3390\/ijms21020449.","journal-title":"IJMS"},{"key":"4516_CR13","doi-asserted-by":"publisher","first-page":"1456939","DOI":"10.3389\/fnano.2024.1456939","volume":"6","author":"PD Ly","year":"2024","unstructured":"Ly PD, Ly KN, Phan HL, Nguyen HHT, Duong VA, Nguyen HV. Recent advances in surface decoration of nanoparticles in drug delivery. Front Nanotechnol. 2024;6:1456939. https:\/\/doi.org\/10.3389\/fnano.2024.1456939.","journal-title":"Front Nanotechnol"},{"key":"4516_CR14","doi-asserted-by":"publisher","first-page":"100529","DOI":"10.1016\/j.rsurfi.2025.100529","volume":"19","author":"S Islam","year":"2025","unstructured":"Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery\u2013A review. Results Surf Interfaces. 2025;19:100529. https:\/\/doi.org\/10.1016\/j.rsurfi.2025.100529.","journal-title":"Results Surf Interfaces"},{"issue":"5","key":"4516_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.3390\/pharmaceutics14051113","volume":"14","author":"TA Seidu","year":"2022","unstructured":"Seidu TA, Kutoka PT, Asante DO, Farooq MA, Alolga RN, Bo W. Functionalization of nanoparticulate drug delivery systems and its influence in cancer therapy. Pharmaceutics. 2022;14(5):1113. https:\/\/doi.org\/10.3390\/pharmaceutics14051113.","journal-title":"Pharmaceutics"},{"issue":"1","key":"4516_CR16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Sig Transduct Target Ther. 2023;8(1):418. https:\/\/doi.org\/10.1038\/s41392-023-01642-x.","journal-title":"Sig Transduct Target Ther"},{"key":"4516_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jconrel.2018.01.002","volume":"272","author":"F Charbgoo","year":"2018","unstructured":"Charbgoo F, Nejabat M, Abnous K, Soltani F, Taghdisi SM, Alibolandi M, et al. Gold nanoparticle should understand protein Corona for being a clinical nanomaterial. J Controlled Release. 2018;272:39\u201353. https:\/\/doi.org\/10.1016\/j.jconrel.2018.01.002.","journal-title":"J Controlled Release"},{"issue":"1","key":"4516_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/cancers11010045","volume":"11","author":"Y Kim","year":"2019","unstructured":"Kim Y, Kim Y, Lee S, Yang H, Kim S. Personalized prediction of acquired resistance to EGFR-Targeted inhibitors using a Pathway-Based machine learning approach. Cancers. 2019;11(1):45. https:\/\/doi.org\/10.3390\/cancers11010045.","journal-title":"Cancers"},{"issue":"3","key":"4516_CR19","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1007\/s00396-014-3464-9","volume":"293","author":"M Iqbal","year":"2015","unstructured":"Iqbal M, Valour JP, Fessi H, Elaissari A. Preparation of biodegradable PCL particles via double emulsion evaporation method using ultrasound technique. Colloid Polym Sci. 2015;293(3):861\u201373. https:\/\/doi.org\/10.1007\/s00396-014-3464-9.","journal-title":"Colloid Polym Sci"},{"key":"4516_CR20","doi-asserted-by":"publisher","unstructured":"Ahn H. Central Composite Design for the Experiments with Replicate Runs at Factorial and Axial Points. In: Gen M, Kim KJ, Huang X, Hiroshi Y, editors. Industrial Engineering, Management Science and Applications 2015 [Internet]. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015 [cited 2025 Oct 5]. pp. 969\u201379. (Lecture Notes in Electrical Engineering; vol. 349). Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-662-47200-2_101","DOI":"10.1007\/978-3-662-47200-2_101"},{"issue":"18","key":"4516_CR21","doi-asserted-by":"publisher","first-page":"5432","DOI":"10.3390\/molecules26185432","volume":"26","author":"H Hassan","year":"2021","unstructured":"Hassan H, Adam SK, Alias E, Meor Mohd Affandi MMR, Shamsuddin AF, Basir R. Central composite design for formulation and optimization of solid lipid nanoparticles to enhance oral bioavailability of acyclovir. Molecules. 2021;26(18):5432. https:\/\/doi.org\/10.3390\/molecules26185432.","journal-title":"Molecules"},{"issue":"12","key":"4516_CR22","doi-asserted-by":"publisher","first-page":"e32953","DOI":"10.1016\/j.heliyon.2024.e32953","volume":"10","author":"D Amer Ali","year":"2024","unstructured":"Amer Ali D, Ibrahim ME. Optimization using central composite design for continuous absorption of CO2 gas with green sodium silicate in a packed bed column. Heliyon. 2024;10(12):e32953. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e32953.","journal-title":"Heliyon"},{"issue":"4","key":"4516_CR23","doi-asserted-by":"publisher","first-page":"e70028","DOI":"10.1002\/bip.70028","volume":"116","author":"S Batheja","year":"2025","unstructured":"Batheja S, Sahoo RK, Rani S, Gupta S, Tejavath KK, Sinha S, et al. Central composite design based optimization of carbohydrate coated albumin nanoparticles for HCC: Synthesis, extensive characterization and in vivo Pharmacokinetic evaluation. Biopolymers. 2025;116(4):e70028. https:\/\/doi.org\/10.1002\/bip.70028.","journal-title":"Biopolymers"},{"issue":"13","key":"4516_CR24","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1080\/01932691.2022.2099888","volume":"44","author":"D Panjwani","year":"2023","unstructured":"Panjwani D, Patel S, Mishra D, Patel V, Yadav M, Dharamsi A, et al. Avidin-Biotin functionalized self-assembled protein nanoparticles as EGFR targeted therapeutics for the treatment of lung cancer: characterization and cell viability. J Dispers Sci Technol. 2023;44(13):2483\u201396. https:\/\/doi.org\/10.1080\/01932691.2022.2099888.","journal-title":"J Dispers Sci Technol"},{"key":"4516_CR25","doi-asserted-by":"publisher","unstructured":"Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research*. J Cereb Blood Flow Metab. 2020;40(9). https:\/\/doi.org\/10.1177\/0271678X2094.","DOI":"10.1177\/0271678X2094"},{"issue":"12","key":"4516_CR26","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/pharmaceutics13122153","volume":"13","author":"I Van Zundert","year":"2021","unstructured":"Van Zundert I, Bravo M, Deschaume O, Cybulski P, Bartic C, Hofkens J, et al. Versatile and robust method for antibody conjugation to nanoparticles with high targeting efficiency. Pharmaceutics. 2021;13(12):2153. https:\/\/doi.org\/10.3390\/pharmaceutics13122153.","journal-title":"Pharmaceutics"},{"key":"4516_CR27","doi-asserted-by":"publisher","unstructured":"\u00dcnal S, Do\u011fan O, Akta\u015f Y, Paclitaxel-loaded polycaprolactone nanoparticles for lung tumors; formulation, comprehensive in vitro characterization and release kinetic studies. Ankara Universitesi Eczacilik Fakultesi Dergisi. 2022;46(3). https:\/\/doi.org\/10.33483\/jfpau.1161238.","DOI":"10.33483\/jfpau.1161238"},{"key":"4516_CR28","doi-asserted-by":"publisher","first-page":"103456","DOI":"10.1016\/j.mtcomm.2022.103456","volume":"31","author":"MW Qureshi","year":"2022","unstructured":"Qureshi MW, Ma X, Tang G, Paudyal D. Investigating a novel magnetic MAX phase nitride and its (001)-surfaces. Mater Today Commun. 2022;31:103456. https:\/\/doi.org\/10.1016\/j.mtcomm.2022.103456.","journal-title":"Mater Today Commun"},{"issue":"1","key":"4516_CR29","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12951-015-0086-4","volume":"13","author":"B Wang","year":"2015","unstructured":"Wang B, Yu XC, Xu SF, Xu M. Paclitaxel and Etoposide co-loaded polymeric nanoparticles for the effective combination therapy against human osteosarcoma. J Nanobiotechnol. 2015;13(1):22. https:\/\/doi.org\/10.1186\/s12951-015-0086-4.","journal-title":"J Nanobiotechnol"},{"key":"4516_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1146\/annurev-pharmtox-010715-103456","volume":"56","author":"R Tong","year":"2016","unstructured":"Tong R, Kohane DS. New strategies in cancer nanomedicine. Annu Rev Pharmacol Toxicol. 2016;56:41\u201357.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"4516_CR31","doi-asserted-by":"publisher","unstructured":"Zhao N, Ding B, Zhang Y, Klockow JL, Lau K, Chin FT, et al. Reactive oxygen species and enzyme dual-responsive biocompatible drug delivery system for targeted tumor therapy. J Controlled Release. 2020;324. https:\/\/doi.org\/10.1016\/j.jconrel.2020.05.031.","DOI":"10.1016\/j.jconrel.2020.05.031"},{"key":"4516_CR32","doi-asserted-by":"publisher","unstructured":"Singh R, Singh S. Redox-dependent catalase mimetic cerium oxide-based nanozyme protect human hepatic cells from 3-AT induced acatalasemia. Colloids Surf B Biointerfaces. 2019;175. https:\/\/doi.org\/10.1016\/j.colsurfb.2018.12.042.","DOI":"10.1016\/j.colsurfb.2018.12.042"},{"issue":"2","key":"4516_CR33","doi-asserted-by":"publisher","first-page":"248","DOI":"10.3390\/cancers11020248","volume":"11","author":"K Huang","year":"2019","unstructured":"Huang K, Cui D, Zhang B, Liu H, Wang L, Fan J, et al. Decoration of Anti-CD38 on nanoparticles carrying a STAT3 inhibitor can improve the therapeutic efficacy against myeloma. Cancers (Basel). 2019;11(2):248. https:\/\/doi.org\/10.3390\/cancers11020248.","journal-title":"Cancers (Basel)"},{"key":"4516_CR34","doi-asserted-by":"publisher","first-page":"6825","DOI":"10.2147\/IJN.S331210","volume":"16","author":"W-T Cheng","year":"2021","unstructured":"Cheng W-T, Ho H-O, Lin S-Y, Liu D-Z, Chen L-C, Sheu M-T, et al. Carfilzomib and Paclitaxel Co-Loaded protein nanoparticles an effective therapy against pancreatic adenocarcinomas. Int J Nanomed. 2021;16:6825\u201341. https:\/\/doi.org\/10.2147\/IJN.S331210.","journal-title":"Int J Nanomed"},{"key":"4516_CR35","doi-asserted-by":"publisher","first-page":"120703","DOI":"10.1016\/j.ijpharm.2021.120703","volume":"603","author":"Y Jun","year":"2021","unstructured":"Jun Y, Jo H, Lee J, Oh H, Cho S, Song J, et al. Quinic acid\u2013functionalized nanoparticles for improved tumor targeting and enhanced anticancer efficacy of Carfilzomib. Int J Pharm. 2021;603:120703. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120703.","journal-title":"Int J Pharm"},{"issue":"13","key":"4516_CR36","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1039\/D1BM00487A","volume":"9","author":"T Cheng","year":"2021","unstructured":"Cheng T, Li J, Zhang Y, Zhang X, Qu Y, Niu Y, et al. Carfilzomib and Paclitaxel co-loaded protein nanoparticles: an effective therapy against pancreatic adenocarcinomas. Biomater Sci. 2021;9(13):4639\u201352. https:\/\/doi.org\/10.1039\/D1BM00487A.","journal-title":"Biomater Sci"},{"key":"4516_CR37","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s10965-022-03362-2","volume":"30","author":"S Patel","year":"2023","unstructured":"Patel S, Patel V, Yadav M, et al. Development of surface Conjugated block Co polymeric micelles as targeted therapeutics: characterization and in-vitro cell viability. J Polym Res. 2023;30:14. https:\/\/doi.org\/10.1007\/s10965-022-03362-2.","journal-title":"J Polym Res"},{"key":"4516_CR38","doi-asserted-by":"publisher","unstructured":"Patel S, Shah Y, Patel V, Patel A, Panjwani D, Ahlawat P. Formulation and ex vivo characterization of lipid-coated clozapine albumin nanoparticles for intranasal delivery in schizophrenia management. J Dispers Sci Technol. 2025;1\u201315. https:\/\/doi.org\/10.1080\/01932691.2025.2548257.","DOI":"10.1080\/01932691.2025.2548257"},{"issue":"13","key":"4516_CR39","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1080\/01932691.2022.2099888","volume":"44","author":"D Panjwani","year":"2023","unstructured":"Panjwani D, Patel S, Mishra D, Patel V, Yadav M, Dharamsi A, Patel A. Avidin-Biotin functionalized self-assembled protein nanoparticles as EGFR targeted therapeutics for the treatment of lung cancer: characterization and cell viability. J Dispers Sci Technol. 2023;44(13):2483\u201396. https:\/\/doi.org\/10.1080\/01932691.2022.2099888.","journal-title":"J Dispers Sci Technol"},{"key":"4516_CR40","doi-asserted-by":"publisher","unstructured":"Darshan Gevariya L, Priya S, Mehta V, Patel D, Bhuva D, Panjwani S, Patel P, Ahlawat A, Dharamsi A, Patel. Bio-Functional mesoporous silica nanoparticles as Nano-Structured carriers in cancer theranostic review on recent advancements, Current Drug Targets; 24, Issue 12, Year 2023, e170823219905.https:\/\/doi.org\/10.2174\/1389450124666230817103122","DOI":"10.2174\/1389450124666230817103122"},{"key":"4516_CR41","doi-asserted-by":"publisher","first-page":"124350","DOI":"10.1016\/j.jchromb.2024.124350","volume":"1249","author":"A Drishti Panjwani","year":"2024","unstructured":"Drishti Panjwani A, Patel D, Mishra S, Patel V, Patel MR, Yadav B, Singh. Green RP-HPLC method for the Estimation of Carfilzomib in bulk, protein nanocarriers and human plasma: application of chemometrics and Monte-Carlo simulations. J Chromatogr B. 2024;1249:124350. https:\/\/doi.org\/10.1016\/j.jchromb.2024.124350.","journal-title":"J Chromatogr B"},{"key":"4516_CR42","doi-asserted-by":"publisher","unstructured":"Patel M, Saha N, Patel S, Ahlawat P, Dharamsi A, Patel A. Development of Bromfenac Sodium Loaded Pluronic Nanomicelles: Characterization and Corneal Permeation Study, Recent Advances in Drug Delivery and Formulation; Volume 16, Issue 1, Year 2022, e280122200656. https:\/\/doi.org\/10.2174\/2667387816666220128123737","DOI":"10.2174\/2667387816666220128123737"},{"key":"4516_CR43","doi-asserted-by":"publisher","unstructured":"Patel A, Patel A, Patel R, Dharamsi A. Application of Failure Mode Effect Analysis in Wurster-Based Pelletization Technology: a Technical Note. AAPS PharmSciTech. 2019;20(8):324. https:\/\/doi.org\/10.1208\/s12249-019-1516-7.","DOI":"10.1208\/s12249-019-1516-7"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04516-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T09:33:26Z","timestamp":1775036006000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4516"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04516-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All in vivo experiments on animal were ethically approved by the Institutional Animal Care and Use Committee of\n                      IAEC Approval No\n                      : IAEC\/PIPH\/023. The MM2 cell line was procured from ATCC, Sigma Aldrich, Mumbai. The experimentation was performed in lab without using any animal or human source. All animal experimental procedures were reviewed and approved by the Institutional Animal Ethics Committee (IAEC) under approval number IAEC\/PIPH\/023, and were conducted in accordance with the guidelines of the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), Government of India. Not applicable. The research work does not involve human participants for the experimentation. So, no consent of participation is applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This study does not contain any individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"526"}}